Multikinase inhibitor (VEGFR-targeted TKI): Class Overview and Comparison
Quick answer: Multikinase inhibitor (VEGFR-targeted TKI) are a class of medicines used for specific therapeutic indications. iMedic covers 1 multikinase inhibitor (vegfr-targeted tki) substances. Below is a comparison table linking to detailed pages for each.
Multikinase inhibitor (VEGFR-targeted TKI) on iMedic (1 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Kisplyx | Advanced renal cell carcinoma, Hepatocellular carcinoma | Lenvatinib inhibits VEGFR1-3, FGFR1-4, PDGFRα, KIT and RET, blocking tumor angio | 18-24 mg orally once daily (indication-dependent) |
About Multikinase inhibitor (VEGFR-targeted TKI)
Multikinase inhibitor (VEGFR-targeted TKI) share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are Multikinase inhibitor (VEGFR-targeted TKI)?
Multikinase inhibitor (VEGFR-targeted TKI) are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 1 substances in this class with detailed pages for each.
Are all Multikinase inhibitor (VEGFR-targeted TKI) interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different Multikinase inhibitor (VEGFR-targeted TKI)?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are Multikinase inhibitor (VEGFR-targeted TKI) available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.